Compare

CagriSema vs Retatrutide

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

CagriSema

246 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 60% · Mixed 26% · Unfavorable overall 14%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
-107
Focus
-71
Sleep quality
-44
Lean mass
-63
Joint comfort
-155

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Fatigue
-11
Nausea
9
Water retention
-79
Appetite loss
-67
Injection site reaction
-156

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.1–2 mg

0.1–0.2 mg
7
0.2–0.4 mg
11
0.4–0.6 mg
21
0.6–1 mg
15
1–2 mg
4

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing50stacking23side effects26cagrisema29

How repeat users are trending

Among repeat reporters, 55% said they felt similar to their last entry, 40% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 20 days · Based on 54 repeat reporters

Retatrutide

381 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 45% · Mixed 38% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
-72
Digestive comfort
-134
Skin appearance
-74
Appetite control
-44
Energy
-40

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Anxiety
-156
Flushing
-54
Headache
-109
GI discomfort
-49
Dizziness
-41

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0.025–2 mg

0.025–0.05 mg
1
0.05–0.1 mg
9
0.1–0.2 mg
12
0.2–0.4 mg
17
0.4–0.6 mg
9
0.6–1 mg
6
1–2 mg
1

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing25stacking38side effects11retatrutide14

How repeat users are trending

Among repeat reporters, 55% said they felt similar to their last entry, 31% more positive, and 15% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 14 days · Based on 84 repeat reporters

Sources (7)

Published sources linked on the CagriSema and Retatrutide wiki pages.

  1. PubMed

    Cagrilintide plus semaglutide for obesity: a randomized phase 2 trial

    Frias JP, Deenadayalan S, Erichsen L, et al. Nat Med. 2023

    Source
    Wiki study page →
  2. PubMed

    Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes

    Rosenstock J, Frias J, Jastreboff AM, et al. Lancet. 2023

    Source
    Wiki study page →
  3. PubMed

    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

    Jastreboff AM, Kaplan LM, Frias JP, et al. N Engl J Med. 2023

    Source
    Wiki study page →
  4. ClinicalTrials.gov

    Retatrutide obesity studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  5. ClinicalTrials.gov

    Retatrutide studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  6. PubMed

    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

    Jastreboff AM, Kaplan LM, Frías JP, et al. The New England journal of medicine. 2023

    Source
    Wiki study page →
  7. PubMed

    Retatrutide-A Game Changer in Obesity Pharmacotherapy

    Katsi V, Koutsopoulos G, Fragoulis C, et al. Biomolecules. 2025

    Source
    Wiki study page →